Last Update 24 Jul 26
Fair value Decreased 82%HUMA: V012 Phase 3 Data Will Drive Dialysis Access Opportunity
Humacyte's updated analyst price target of $4.00, along with shifts in fair value and key assumptions such as discount rate, revenue growth, profit margin, and future P/E, reflects analysts' response to recent positive V012 Phase 3 interim data, evolving indication expansion expectations, and refreshed long term revenue projections across dialysis and vascular applications.
Analyst Commentary
Recent research coverage on Humacyte highlights a mix of optimism around the V012 Phase 3 interim data, expectations for regulatory progress, and ongoing adjustments to revenue and indication assumptions. While individual price targets vary, the common thread is that analysts are refining their models as they incorporate new clinical and commercial inputs.
Several firms describe the V012 top-line results as supportive of Humacyte's planned regulatory filings for acellular tissue engineered vessels in dialysis access, and they are updating their fair value work to reflect evolving views on uptake across dialysis and broader vascular use cases.
Bullish Takeaways
- Bullish analysts have raised price targets to a range of roughly US$2 to US$4, reflecting increased confidence that the V012 interim data and physician feedback support Humacyte's longer term dialysis opportunity and wider vascular applications.
- The view that the V012 study met its primary endpoint with positive secondary analyses is seen as a validation point for Humacyte's acellular tissue engineered vessel platform, which bullish analysts describe as important for execution on future indication expansion.
- Some bullish analysts explicitly tie their higher valuation work to updated revenue projections for the dialysis indication, including detailed U.S. revenue paths from the late 2020s into the 2030s, underscoring their conviction that the asset can build a meaningful commercial footprint over time.
- Beyond dialysis, bullish analysts point to potential expansion into areas such as vascular trauma, AV access, CABG, and PAD as important longer term growth drivers that support constructive views on Humacyte's runway and keep upward pressure on longer term fair value assumptions.
What’s in the News for Humacyte
- Humacyte reported detailed V012 Phase 3 results for its acellular tissue engineered vessel in female dialysis patients, with ATEV showing more catheter free days, fewer infections and a favorable overall safety profile compared with AV fistula. The company plans to file a supplemental BLA with the FDA in the second half of 2026 for adult end stage kidney disease patients at higher risk of fistula maturation failure. (Source: Company product related announcements)
- The company completed a US$50m follow on equity offering of 47,619,048 common shares at US$1.05 per share, with a stated discount of US$0.063 per share. It also filed a separate follow on equity offering for its common stock. (Source: Follow on equity offering announcements)
- Humacyte received stockholder approval at its 2026 Annual Meeting to amend its certificate of incorporation, increasing authorized common shares from 350,000,000 to 550,000,000, effective upon filing with the Delaware Secretary of State. (Source: Changes in company bylaws/rules)
- The company disclosed multiple lock up agreements on restricted stock units, warrants, common stock and stock options. Restrictions are in place from June 10, 2026 through August 10, 2026 that limit certain sales and hedging activity without underwriter consent. (Source: Lock up period disclosures)
- Humacyte received a Nasdaq notice that its common stock bid price had closed below the US$1.00 minimum for 30 consecutive business days, triggering a 180 day period through November 2, 2026 to regain compliance by maintaining at least US$1.00 for 10 consecutive business days. The stock remains listed on the Nasdaq Global Select Market under ticker HUMA. (Source: Nasdaq listing compliance notice)
Valuation Changes for Humacyte
- Fair Value: The updated analyst fair value moved from approximately $22.83 to $4.00, indicating a very large reset in modeled equity value per share.
- Discount Rate: The discount rate increased slightly from about 7.44% to 7.76%, implying a modestly higher required return in updated models.
- Revenue Growth: Revenue growth assumptions shifted from a very large prior figure to 392.18%, pointing to a materially lower, but still very high, projected growth rate.
- Net Profit Margin: Profit margin expectations moved from 61.76% to 14.16%, marking a substantial reduction in modeled long term profitability for Humacyte.
- Future P/E: The future P/E multiple increased from 15.89x to 39.85x, indicating that a higher valuation multiple is now being applied to Humacyte's projected earnings stream.
Catalysts
About Humacyte
Humacyte develops off the shelf bioengineered human vessels for vascular trauma, dialysis access and other cardiovascular applications.
What are the underlying business or industry changes driving this perspective?
- Growing adoption of Symvess in civilian trauma centers, supported by 92 hospitals already eligible to purchase and reports that most early customers are reordering, directly supports potential revenue growth as usage patterns deepen.
- Access to U.S. military and Veterans Affairs facilities through ECAT listing and the positive Ukraine humanitarian data in real world combat injuries position Symvess to benefit from long term demand for vascular solutions in defense and veteran care, which could broaden the revenue base.
- Positive Phase III results for the ATEV in dialysis access, targeting women and high risk men who represent more than half of the dialysis population, align with a large, chronically treated patient group that could influence longer term revenue and earnings if an added indication is approved.
- Planned first in human studies for the coronary tissue engineered vessel in CABG, where few new conduits have entered U.S. practice in decades, offer a potential entry into a large cardiac surgery market that could add new revenue streams over time.
- Expansion of the patent estate covering multiple tubular organs, including esophagus, trachea and urinary conduits with protection into 2041, helps support pricing power and potential future product extensions, which can be important for margin stability and long term earnings potential.
Assumptions
How have these above catalysts been quantified?
- This narrative explores a more optimistic perspective on Humacyte compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts.
- The bullish analysts are assuming Humacyte's revenue will grow by 392.2% annually over the next 3 years.
- The bullish analysts assume that profit margins will increase from -4723.1% today to 14.2% in 3 years time.
- The bullish analysts expect earnings to reach $34.0 million (and earnings per share of $0.14) by about July 2029, up from -$95.2 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $-43.0 million.
- In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 40.0x on those 2029 earnings, up from -1.8x today. This future PE is greater than the current PE for the US Biotechs industry at 16.9x.
- The bullish analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 7.76%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?
- Humacyte is still in the early stages of commercialization, with third quarter 2025 revenue of US$0.8 million and US$1.6 million for the first nine months of 2025, while net cash used in operating activities was US$78.9 million over that same nine month period. If revenue does not scale meaningfully relative to cash burn, future dilution or funding pressure could weigh on earnings and shareholder returns.
- Symvess uptake currently depends on hospital Value Analysis Committee approvals, price sensitive purchasing departments and individual surgeon champions. Humacyte has already reduced price to help move VAC processes along. Slower than hoped adoption, pushback on pricing or limited reorder volumes could hold back product sales growth and keep gross margin and operating margin under pressure.
- The dialysis access opportunity relies on positive interim results from the V012 Phase III trial and on a supplemental BLA filing planned for the second half of 2026. Any delay, inconclusive data or regulatory hurdle for ATEV in dialysis could postpone or shrink a key long term revenue stream that bullish expectations currently assume will support higher earnings.
- The broader pipeline beyond trauma and dialysis, including coronary artery bypass grafting and tubular organ programs such as esophagus, trachea and urinary conduits, is at preclinical or very early clinical stages and not currently a focus of active development. If these programs remain deprioritized because of cash constraints or technical challenges, the long dated product portfolio that some investors may expect to diversify revenue and improve margins might not materialize.
- Humacyte finished September 30, 2025 with US$19.8 million in cash, cash equivalents and restricted cash and then raised an additional US$56.5 million, which management believes provides runway exceeding 12 months. If operating cash use remains high or increases with inventory build, commercial expansion and new trials, the company may need further capital sooner than investors expect, which could dilute existing shareholders and weigh on per share earnings.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The assumed bullish price target for Humacyte is $4.0, which represents up to two standard deviations above the consensus price target of $2.05. This valuation is based on what can be assumed as the expectations of Humacyte's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $4.0, and the most bearish reporting a price target of just $1.0.
- In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2029, revenues will be $240.4 million, earnings will come to $34.0 million, and it would be trading on a PE ratio of 40.0x, assuming you use a discount rate of 7.8%.
- Given the current share price of $0.64, the analyst price target of $4.0 is 84.0% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Humacyte?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystHighTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystHighTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystHighTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
